Managing long-term antithrombotic therapy in ischemic stroke survivors demands a careful balance between preventing recurrent ischemia and avoiding devastating hemorrhagic complications. Among these adverse bleeding events, post-stroke subdural hematoma has emerged as an increasingly prevalent concern in aging populations. Subdural bleeding can rapidly compromise functional recovery and increase mortality, particularly when patients receive antiplatelet or anticoagulant medications. However, clinical guidelines offer limited guidance regarding subtype-specific risk stratification for traumatic versus non-traumatic subdural hematoma. Furthermore, conventional predictive studies frequently fail to account for competing mortality risks in frail stroke survivors. Consequently, clinicians require robust tools to identify high-risk individuals and tailor long-term surveillance. A groundbreaking nationwide cohort study provides vital insights into predicting both traumatic and non-traumatic subdural hematoma following ischemic stroke.

Clinical Burden of Post-Stroke Subdural Hematoma

Subdural hematoma represents a formidable challenge in post-stroke care because it involves bleeding between the arachnoid and dura mater. Over recent decades, expanding antithrombotic indications and an aging demographic have substantially increased the incidence of subdural bleeding. In this nationwide investigation involving 506,746 ischemic stroke survivors, researchers followed patients for a median of 57.9 months. During this surveillance period, 7,425 individuals experienced traumatic subdural hematoma, while 1,705 developed non-traumatic subdural hematoma. Therefore, the 10-year cumulative incidence reached 1.94% for traumatic events and 0.43% for non-traumatic events.

These figures underscore that traumatic head injury accounts for the vast majority of subdural hematomas in stroke survivors. Physical frailty, gait impairment, and sensory deficits make post-stroke patients particularly susceptible to accidental falls. However, spontaneous or non-traumatic subdural hematomas still represent a critical clinical threat with substantial morbidity. Although non-traumatic events occur less frequently, their insidious onset often delays diagnosis and worsens neurological recovery. Moreover, the risk accumulates steadily across the post-stroke continuum rather than plateauing after the acute phase. Clinicians must recognize that long-term survival after an ischemic cerebrovascular event requires constant vigilance for intracranial hemorrhage. Consequently, understanding distinct baseline risks across these two subtypes enables healthcare teams to implement targeted protective measures.

Methodological Rigor and the Competing Risk Approach

Traditional survival models often overestimate long-term hemorrhage rates because they treat all-cause mortality as simple uninformative censoring. In reality, ischemic stroke survivors face substantial competing mortality risks from recurrent vascular events, cardiac complications, and advanced age. To address this methodological challenge, investigators applied Fine-Gray subdistribution hazard regression alongside cause-specific hazard models using data from the Korean National Health Insurance Service from 2010 to 2023. By accounting for competing mortality, the researchers generated realistic cumulative incidence projections rather than inflated risk estimates.

Furthermore, the research team employed the Akaike Information Criterion to select the most predictive yet parsimonious clinical variables. They subsequently converted these variables into practical, integer-based risk scores that clinicians can quickly calculate. Internal cross-validation demonstrated consistent model accuracy across diverse patient subgroups. To ensure international applicability, the authors also externally validated the prediction models in an independent ischemic stroke cohort from the UK Biobank. Remarkably, the models maintained robust risk-gradient separation and reliable discriminatory performance across distinct geographic and demographic populations. Thus, this dual-cohort design confirms the generalizability of the findings and establishes a dependable framework for clinical risk stratification.

Differential Predictors of Traumatic and Spontaneous Subdural Bleeding

The study identified crucial differences in the underlying risk factor profiles for traumatic and non-traumatic subdural hematomas. Advanced age, overall multimorbidity, and antithrombotic drug exposure independently heightened the hazard for both hemorrhagic subtypes. Nevertheless, distinct clinical drivers governed each specific presentation. Specifically, traumatic subdural hematoma demonstrated much stronger correlations with antiplatelet therapy, older age, and diabetes mellitus. Because diabetes often causes diabetic neuropathy, retinopathy, and autonomic instability, it elevates fall risk and predisposes vulnerable patients to head trauma.

Conversely, non-traumatic subdural hematoma showed its strongest statistical correlation with oral anticoagulant therapy, especially warfarin use. Unlike traumatic lesions triggered by shearing bridging veins during physical impact, spontaneous subdural bleeding often arises from fragile dural capillaries or microvascular leakage. In this context, systemic anticoagulation facilitates continuous microscopic oozing, which eventually forms a symptomatic subdural collection. Furthermore, renal disease, liver dysfunction, and cerebral amyloid angiopathy can exacerbate systemic coagulopathy and vascular friability. Consequently, identifying these diverging risk factors allows physicians to distinguish between patients who need fall-prevention interventions and those who require meticulous coagulation monitoring.

Antithrombotic Stewardship and Warfarin Optimization

Among all evaluated clinical variables, warfarin therapy emerged as the single most important modifiable risk factor for non-traumatic subdural hematoma. Although vitamin K antagonists effectively prevent recurrent thromboembolism in valvular and non-valvular atrial fibrillation, their narrow therapeutic window poses persistent bleeding hazards. Fluctuation in the international normalized ratio significantly magnifies microvascular bleeding risks within the subdural space. In contrast, non-vitamin K antagonist oral anticoagulants demonstrate a more favorable intracranial safety profile, which highlights an important avenue for clinical optimization.

However, researchers emphasize that high subdural hematoma risk scores should never prompt reflexive or premature antithrombotic cessation. Withholding indicated antithrombotic therapy markedly increases the hazard of devastating ischemic stroke recurrence, myocardial infarction, and systemic thromboembolism. Instead, clinicians must practice comprehensive antithrombotic stewardship by balancing ischemic hazards against specific bleeding risks. For example, doctors should eliminate unnecessary concomitant antiplatelet medications in patients taking anticoagulants, optimize international normalized ratio control, or transition eligible patients to safer anticoagulant alternatives. Additionally, clinicians should treat hypertension aggressively, address heavy alcohol consumption, and review potential drug-drug interactions that impair coagulation. Through systematic risk mitigation, healthcare providers can preserve cardiovascular protection while minimizing subdural hemorrhage danger.

Implementing Digital Risk Calculators in Routine Care

To bridge the gap between complex epidemiological models and daily bedside decision-making, the study authors developed an accessible, web-enabled risk calculator. This practical digital platform integrates routinely available demographic and clinical variables to generate individualized 10-year cumulative incidence projections for both subdural hematoma subtypes. Consequently, clinicians can swiftly estimate risk during outpatient visits without requiring expensive biomarkers or advanced neuroimaging.

Importantly, these prediction tools serve specific clinical functions in outpatient neurology, cardiology, and primary care settings. First, they facilitate personalized patient counseling by providing concrete risk numbers that empower shared decision-making. Second, high risk scores alert clinicians to implement aggressive fall-prevention strategies, such as physical therapy, home safety modifications, assistive walking devices, and medication reconciliation for sedatives. Third, the tool guides structured clinical surveillance, encouraging prompt neuroimaging whenever high-risk patients report subtle headaches, cognitive slowing, or minor falls. Finally, integrating these validated models into electronic health record workflows can automate risk alerts and standardize post-stroke antithrombotic monitoring across diverse healthcare environments.

Frequently Asked Questions

What is the 10-year cumulative incidence of post-stroke subdural hematoma?

In ischemic stroke survivors, the 10-year cumulative incidence is approximately 1.94% for traumatic subdural hematoma and 0.43% for non-traumatic subdural hematoma. Traumatic events occur far more frequently because post-stroke neurological deficits, gait instability, and sensory impairments dramatically elevate the lifetime risk of accidental falls.

Why should clinicians avoid stopping antithrombotic therapy based solely on subdural hematoma risk scores?

Discontinuing antithrombotic therapy in isolation drastically increases the risk of recurrent ischemic stroke and systemic thromboembolism. Instead of stopping medications, clinicians should use risk scores to guide fall-prevention measures, eliminate unnecessary dual antithrombotic therapy, optimize blood pressure, and select safer anticoagulation regimens.

How does diabetes mellitus increase the risk of traumatic subdural hematoma?

Diabetes mellitus accelerates peripheral neuropathy, impairs vision, and causes autonomic orthostatic hypotension, which substantially increases the likelihood of accidental falls. When diabetic stroke survivors fall and experience head impacts, concurrent antiplatelet therapy exacerbates tearing of bridging veins, leading to acute or chronic subdural collections.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Consult qualified healthcare professionals for diagnosis and treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Kim J et al. Risk prediction of traumatic and non-traumatic subdural hematoma after ischemic stroke: a nationwide competing-risk model with external validation. Neurosurg Rev. 2026 Aug 03. doi: 10.1007/s10143-026-04414-7. PMID: 42545518.

2. Gaist D, García Rodríguez LA, Hellfritzsch M, et al. Association of Antithrombotic Drug Use With Subdural Hematoma Risk. JAMA. 2017;317(8):836–846. doi:10.1001/jama.2017.0639.

3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in stroke prevention: intracranial hemorrhage and antithrombotic therapy. Stroke. 2014;45(5):1300–1306. doi:10.1161/STROKEAHA.113.003882.